Canterbury DHB
Aim: to prevent spontaneous bleeding.
This is generally achieved by a peak factor IX of 40%.
Treatment is normally given twice weekly.
In patients with a shorter half life or breakthrough bleeds, the dosing should be increased. A dose up to 60 u/kg/dose may be required. Dosing three times a week should be considered if breakthrough bleeds are a problem. It is advisable to calculate the recovery and half-life in all cases. In some cases, it may be necessary to individualise treatment and recommend more frequent administration.
Topic Code: 5311